EUCTR2011-002166-20-ES进行中（未招募）1 期
Treatment of hepatorenal syndrome with terlipressin infusion adjusted to hemodynamic response
Fundació Clinic per a la Recerca Biomèdica0 个研究点开始时间: 2012年1月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Patients with type 1 HRS.
- •- Signed Informed consent.
- •- No exclusion criteria.
- •- Age> 18 years old
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Hepatocellular carcinoma: exclusion of patients with hepatocellular carcinoma having more than 3 nodules, single nodule larger than 5 cm, tumor portal vein thrombosis or extrahepatic tumor spread.
- •- Active bacterial infection with symptoms of systemic inflammatory response (fever, tachycardia, tachypnea, hypotension or septic CBC).
- •- Cardiac or respiratory failure clinically significant.
- •- Clinically significant peripheral artery disease.
- •- A history of ischemic heart disease.
- •- Hypersensitivity to terlipressin and / or albumin or any of the excipients.
- •- Pregnancy.
- •- Septic shock.
- •- Chronic renal failure.
研究者
相似试验
Unknown
4 期
Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic ResponseHepatorenal Syndrome Type ICirrhosisNCT01530711Pere Gines40
暂停
4 期
Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs AlbuminHepatorenal SyndromeCirrhosisNCT00287664Hospital Clinic of Barcelona100
尚未招募
1 期
Terlipressin for the treatment of refractory hypotension in patients otherwise ready for discharge.HypotensionCardiovascular diseaseACTRN12624000364572Sir Charles Gairdner Hospital20
已完成
3 期
TYPE 2 HEPATORENAL SYNDROMESafety and Efficacy of Terlipressin and Noradrenaline and Predictive Factors of Response in Type 2 HRSNCT01637454Post Graduate Institute of Medical Education and Research, Chandigarh46
Unknown
4 期
The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial PressureHepatorenal SyndromeNCT02489864Sun Yat-sen University30